Acitretin (Page 3 of 10)
CLINICAL STUDIES
In 2 double-blind, placebo-controlled trials, acitretin was administered once daily to subjects with severe psoriasis (e.g., covering at least 10% to 20% of the body surface area). At 8 weeks (see Table 1) subjects treated in Trial A with 50 mg of acitretin per day showed significant improvements (P ≤ 0.05) relative to baseline and to placebo in the physician’s global evaluation and in the mean ratings of severity of psoriasis (scaling, thickness, and erythema). In Trial B, differences from baseline and from placebo were statistically significant (P ≤ 0.05) for all variables at both the 25-mg and 50-mg doses; it should be noted for Trial B that no statistical adjustment for multiplicity was carried out.
Efficacy Variables | Trial A | Trial B | |||
Total Daily Dose | Total Daily Dose | ||||
Placebo (N = 29) | 50 mg (N = 29) | Placebo (N = 72) | 25 mg (N = 74) | 50 mg (N = 71) | |
Physician’s Global Evaluation | |||||
Baseline | 4.62 | 4.55 | 4.43 | 4.37 | 4.49 |
Mean Change After 8 Weeks | −0.29 | −2.00a | −0.06 | −1.06a | −1.57a |
Scaling | |||||
Baseline | 4.10 | 3.76 | 3.97 | 4.11 | 4.10 |
Mean Change After 8 Weeks | −0.22 | −1.62a | −0.21 | −1.50a | −1.78a |
Thickness | |||||
Baseline | 4.10 | 4.10 | 4.03 | 4.11 | 4.20 |
Mean Change After 8 Weeks | −0.39 | −2.10a | −0.18 | −1.43a | −2.11a |
Erythema | |||||
Baseline | 4.21 | 4.59 | 4.42 | 4.24 | 4.45 |
Mean Change After 8 Weeks | −0.33 | −2.10a | −0.37 | −1.12a | −1.65a |
a Values were statistically significantly different from placebo and from baseline (P ≤ 0.05). No adjustment for multiplicity was done for Trial B. The efficacy variables consisted of: the mean severity rating of scale, lesion thickness, erythema, and the physician’s global evaluation of the current status of the disease. Ratings of scaling, erythema, and lesion thickness, and the ratings of the global assessments were made using a 7-point scale (0 = none, 1 = trace, 2 = mild, 3 = mild-moderate, 4 = moderate, 5 = moderate-severe, 6 = severe). |
A subset of 141 subjects from both pivotal Trials A and B continued to receive acitretin in an open fashion for up to 24 weeks. At the end of the treatment period, all efficacy variables, as indicated in Table 2, were significantly improved (P ≤ 0.01) from baseline, including extent of psoriasis, mean ratings of psoriasis severity, and physician’s global evaluation.
Variables | Trial A | Trial B |
Mean Total Daily Dose of Acitretin (mg) | 42.8 | 43.1 |
Mean Duration of Therapy (Weeks) | 21.1 | 22.6 |
Physician’s Global Evaluation | N = 39 | N = 98 |
Baseline | 4.51 | 4.43 |
Mean Change from Baseline | −2.26a | −2.60a |
Scaling | N = 59 | N = 132 |
Baseline | 3.97 | 4.07 |
Mean Change from Baseline | −2.15a | −2.42a |
Thickness | N = 59 | N = 132 |
Baseline | 4.00 | 4.12 |
Mean Change from Baseline | −2.44a | −2.66a |
Erythema | N = 59 | N = 132 |
Baseline | 4.35 | 4.33 |
Mean Change from Baseline | −2.31a | −2.29a |
a Indicates that the difference from baseline was statistically significant (P ≤ 0.01). The efficacy variables consisted of: the mean severity rating of scale, lesion thickness, erythema, and the physician’s global evaluation of the current status of the disease. Ratings of scaling, erythema, and lesion thickness, and the ratings of the global assessments were made using a 7-point scale (0 = none, 1 = trace, 2 = mild, 3 = mild-moderate, 4 = moderate, 5 = moderate-severe, 6 = severe). |
All efficacy variables improved significantly in a subset of 55 subjects from Trial A treated for a second, 6-month maintenance course of therapy (for a total of 12 months of treatment); a small subset of subjects (n = 4) from Trial A continued to improve after a third 6-month course of therapy (for a total of 18 months of treatment).
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.